Core Insights - Elutia Inc. has been recognized with two awards in the 2025 Medical Device Network Excellence Awards for its innovations in drug-eluting biomatrix technologies and the successful launch of EluPro [3][4] - EluPro has shown strong commercial performance since its pilot launch in September 2024, with a sequential sales increase of 84% in Q1 2025 and a year-over-year revenue increase of 31% in BioEnvelope sales [4][6] - The product is cleared for use with all major cardiac implantable electronic devices (CIEDs) and neurostimulation devices, addressing complications such as infection and migration [5][6] Company Performance - EluPro was commercially launched in January 2025 and has received approvals from 150 hospital value analysis committees, indicating strong clinical demand [4][6] - The product has established partnerships with seven major group purchasing organizations, reflecting its acceptance within the healthcare procurement ecosystem [4] Product Details - EluPro combines a soft, regenerative biomatrix with antibiotics rifampin and minocycline to enhance healing and reduce complications associated with CIEDs [5][6] - With over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases, EluPro aims to improve patient outcomes significantly [6] Industry Recognition - The Medical Device Network Excellence Awards analyze over 1 billion datasets annually to recognize top-tier companies in the medical device industry [8] - The awards honor innovative companies that drive positive change, highlighting Elutia's commitment to advancing medical technology [8]
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards